Expression and function of RANK in human monocyte chemotaxis

被引:43
作者
Mosheimer, BA [1 ]
Kaneider, NC [1 ]
Feistritzer, C [1 ]
Sturn, DH [1 ]
Wiedermann, CJ [1 ]
机构
[1] Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria
来源
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 07期
关键词
D O I
10.1002/art.20352
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. RANKL, a member of the tumor necrosis factor superfamily, is a central regulator of osteoclast recruitment and activation. Whether RANKL affects monocyte locomotion in vitro via RANK and a possible signaling pathway were investigated. Methods. Monocytes were obtained from venous blood of healthy donors. Cell migration was studied by micropore filter assays. The signaling mechanisms required for RANKL-dependent migration were tested using signaling enzyme blockers and Western blot analyses. Expression of RANK messenger RNA (mRNA) in monocytes was demonstrated by reverse transcriptase-polymerase chain reaction, and receptor expression on cell surface was investigated by fluorescence-activated cell sorting analyses. Results. RANKL significantly stimulated monocyte chemotaxis via activation of phosphatidylinositol 3-kinase, phosphodiesterase, and Src kinase. The effect on migration was inhibited by osteoprotegerin, which is the decoy receptor for RANKL. Expression of RANK receptor mRNA was shown, and synthesis of RANK in monocytes was suggested by the detection of RANK immunoreactivity on the cell surface. Conclusion. These data suggest that RANK is expressed by monocytes whose activation by RANKL stimulates directed migration involving phosphatidylinositol 3-kinase, phosphodiesterase, and Src kinases.
引用
收藏
页码:2309 / 2316
页数:8
相关论文
共 44 条
[1]   Serum osteoprotegerin and its ligand in Paget's disease of bone -: Relationship to disease activity and effect of treatment with bisphosphonates [J].
Alvarez, L ;
Peris, P ;
Guañabens, N ;
Vidal, S ;
Ros, I ;
Pons, F ;
Filella, X ;
Monegal, A ;
Muñoz-Gomez, J ;
Ballesta, AM .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :824-828
[2]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[3]   Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption [J].
Aubin, JE ;
Bonnelye, E .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (11) :905-913
[4]   The receptor activator of nuclear factor (NF)κB ligand (RANKL) is a new chemotactic factor for human monocytes [J].
Breuil, V ;
Schmid-Antomarchi, H ;
Schmid-Alliana, A ;
Rezzonico, R ;
Euller-Ziegler, L ;
Rossi, B .
FASEB JOURNAL, 2003, 17 (10) :1751-+
[5]   HISTOPATHOLOGY OF THE RHEUMATOID LESION - IDENTIFICATION OF CELL-TYPES AT SITES OF CARTILAGE EROSION [J].
BROMLEY, M ;
WOOLLEY, DE .
ARTHRITIS AND RHEUMATISM, 1984, 27 (08) :857-863
[6]   Regulation, substrates and functions of src [J].
Brown, MT ;
Cooper, JA .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (2-3) :121-149
[7]   Rheumatoid arthritis [J].
Feldmann, M ;
Brennan, FM ;
Maini, RN .
CELL, 1996, 85 (03) :307-310
[8]   TRAF6 and C-SRC induce synergistic AP-1 activation via PI3-kinase-AKT-JNK pathway [J].
Funakoshi-Tago, M ;
Tago, K ;
Sonoda, Y ;
Tominaga, S ;
Kasahara, T .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2003, 270 (06) :1257-1268
[9]  
Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO
[10]  
2-P